OKYO Pharma Limited - PDMR Dealing
20 Maio 2022 - 3:00AM
OKYO Pharma Limited - PDMR Dealing
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a life sciences
company focused on the discovery and development of novel molecules
to treat inflammatory dry eye diseases and ocular pain, today
announces that it has been notified that Panetta Partners Limited,
an entity in which Gabriele Cerrone, the Executive Chairman has a
beneficial interest, purchased 5,800,000 ordinary shares of no par
value ("Ordinary Shares") at a price of £0.0625 each (which would
be equivalent to the purchase of 89,230 of the Company's ADSs on
NASDAQ at a price of US$5.08 per ADS).
The acquisition would have increased Mr
Cerrone's beneficial interests in the capital of the Company from
39.64% to 40.06%, however the impact of the offering which closed
yesterday, reduces these holdings to, in aggregate, 39.08% after
allowing for; (i) the dilutive effect of the Ordinary Shares to be
issued in the Offering; and (ii) the 25,000 ADS (representing
1,625,000 Ordinary Shares) purchased by Mr Cerrone in the
Offering).
1. |
Details of PDMR / person closely associated |
a) |
Name |
Gabriele Cerrone |
2. |
Reason for the notification |
a) |
Position / status |
Chairman |
b) |
Initial notification /amendment |
Initial notification |
3. |
Details of the issuer |
a) |
Name |
OKYO Pharma Limited |
b) |
LEI |
213800VVN5CB56Y15A05 |
4. |
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted |
a) |
Description of the financial instrument |
Ordinary Shares of no par value |
b) |
Identification code of the Financial Instrument |
ISIN for OKYO Pharma Limited GG00BD3FV870 |
c) |
Nature of the transaction |
Market Purchase |
d) |
Price(s) and volume(s) |
£0.0625 - 5,800,000 |
f) |
Date of the transaction |
19 May 2022 |
g) |
Place of the transaction |
XLON |
Enquiries:
OKYO Pharma
Limited |
Gary S. Jacob, Chief Executive
OfficerGabriele Cerrone, Non-Executive Chairman |
+44 (0)20 7495 2379 |
|
|
|
Optiva Securities
Limited(Broker) |
Robert Emmet |
+44 (0)20 3981 4173 |
|
|
|
RedChip Companies
Inc.(Investor Relations) |
Dave Gentry |
dave@redchip.com+1
407-491-4498 |
Notes for Editors:
About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is
a life sciences company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the main market for listed securities of London Stock
Exchange plc. OKYO is focusing on the discovery and development of
novel molecules to treat inflammatory dry eye diseases and chronic
pain.
About OK-101
OK-101 is a lipidated chemerin peptide
antagonist of the ChemR23 G-protein coupled receptor which is
typically found on immunological cells of the eye responsible for
the inflammatory response. OK-101 was developed using a
membrane-anchored-peptide (MAP) Technology to produce a novel
long-acting drug candidate for treating DED. OK-101 has been shown
to produce anti-inflammatory activity in mouse models of DED and is
designed to combat washout through the inclusion of the lipid
‘anchor’ contained in the candidate drug molecule to enhance the
residence time of OK-101 within the ocular environment.
About Dry Eye Disease (DED)
Dry eye is a multifactorial disease that results
in ocular discomfort and tear film instability that can lead to
ocular surface damage. It is often a chronic problem, particularly
in older adults, and is expected to become even more prevalent with
the aging population and increased use of digital screens such as
computers and smart phones. Despite new product approvals, dry eye
disease (DED) remains a significant unmet medical need and is one
of the leading causes for patient visits to eye care specialists.
Novel therapies that improve the signs and symptoms of dry eye
disease will be beneficial to dry eye patients.
For further information, please visit the
Company's website at www.okyopharma.com.
Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024